While the Trump administration has not publicly identified the drugmakers and biotechs involved in Operation Warp Speed – its effort to have 300 million doses of a safe and effective COVID-19 vaccine ready by January 2021 – some tiny biotechs have been touting their involvement in the program, sending their stocks soaring. For more, CLICK HERE.
Clinical trial data or regulatory verdicts can send shares of biotech companies skyrocketing – or plummeting. The question then, as the author of today’s article observes, is “how are investors supposed to determine which biotech stocks are capable of outperforming the rest?” One approach is to track analyst sentiment – and the author highlights three biotech stocks that not only are analysts bullish on but which are trading for less than $5 a share and boast upside potential of over 100%. For more, CLICK HERE.
As the end of the second quarter of 2020 approaches, a number of biopharmaceutical companies have data readouts due – and positive trial data could serve as catalysts for those companies’ stocks. For seven biopharmaceutical companies with impending data readouts – and details on their respective potential catalysts – CLICK HERE.
“Biotech penny stocks have always been a big focus for investors but this year has been one of the most active years for the sector,” observes the author of today’s article. And while the coronavirus outbreak has been a major reason for this increased activity, the author notes that “you also have companies hitting big milestones for other health indications.” With this being perhaps one of the best times to bet on biotech penny stocks, the author highlights four in particular to have a look at. For more, CLICK HERE.
When it comes to investors piling into small-cap companies that are developing potential treatments or vaccines for COVID-19 – and causing shares of those companies to take off – Europe is no different than the U.S., with some small-cap biotech names in Europe having seen four-fold gains. Today’s article looks at a number of those companies – and whether investors are likely to end up disappointed. For more, CLICK HERE.
“The tech sector is once again outperforming the overall market in 2020 as investors continue to go all-in on growth,” observes the author of today’s article. However, the tech giants that have led the market’s rise may have limited upside left in the near term, and tech investors may be better off focusing on small-cap tech stocks. For seven high-quality small-cap tech stocks identified as top picks by Bank of America, CLICK HERE.
Based on the premise that tech is poised to continue to drive the market for years to come, today’s article highlights three cheap (trading under $10 a share) stocks from the broader technology space to consider due to their growth prospects regardless of renewed market volatility. For more on these three tech stocks, CLICK HERE.
Shares of the small-cap biotech stock highlighted in today’s article have settled back down after surging more than 70% earlier this month in reaction to interim results for the company’s only drug candidate to reach the clinical trial phase. Does that make now a good time to buy? For more on this “flaming hot” biotech firm that could “become a maverick in developing a therapeutic candidate for [a] significant medical need”, CLICK HERE.
While buying right now may be too risky for the average investor, the small-cap biotech highlighted in today’s article could be worth keeping an eye on, even as it (and many other promising biotech stocks) may have slipped under the radar as attention has shifted to potential COVID-19 plays (which this stock is not). Why? The company’s drug candidate for NASH, a severe form of non-alcoholic fatty liver disease, has posted impressive clinical trial results – and, if ultimately successful, “needs only to gobble up a small portion of the total NASH market to become a mega-blockbuster.” For more, CLICK HERE.
The biotech stock highlighted in today’s article is one of the many that has surged over the last few months due to its status as a potential COVID-19 play, with the company in question being the producer of a COVID-19 test. As with all the smaller biotechs that have been experiencing COVID-19-related surges lately, however, the question is whether that surge is sustainable or justified, and what the best way to play the stock (and its counterparts) may be. For more, CLICK HERE.